NX-5948 Promotes Selective, Sub-Nanomolar Degradation Of Inhibitor-Resistant BTK Mutants By aterrado@waterhousebrands.com / January 7, 2025
First Disclosure Of NX-5948, An Oral Targeted Degrader Of Bruton’s Tyrosine Kinase (BTK) For The Treatment Of B-Cell Malignancies By aterrado@waterhousebrands.com / January 7, 2025
NX-5948: BTK Degrader with Activity in Lymphoid Malignancies By aterrado@waterhousebrands.com / January 7, 2025
NX-5948, A Clinical-Stage BTK Degrader, Achieves Deep Suppression Of BCR, TLR, And Fcr Signaling In Immune Cells And Demonstrates Efficacy In Preclinical Models Of Arthritis And Other Inflammatory Diseases By aterrado@waterhousebrands.com / January 7, 2025
Efficacy And Safety Of The Bruton’s Tyrosine Kinase (BTK) Degrader NX-5948 In Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Results From An Ongoing Phase 1A/B Study By aterrado@waterhousebrands.com / January 7, 2025
Targeting Degraders To The CNS For The Treatment Of Cancer By dev@sirosolutions.com / December 17, 2024
NX-5948, a Brain-Penetrant BTK Degrader with Clinical Activity in B-cell Malignancies Including CNS Lymphoma By dev@sirosolutions.com / December 17, 2024
Latest Results From An Ongoing First-In-Human Phase 1A/B Study Of NX-5948, A Selective Bruton’s Tyrosine Kinase (BTK) Degrader, In Patients With Relapsed/Refractory CLL And Other B-Cell Malignancies By dev@sirosolutions.com / December 17, 2024
The Evolving Chemical Space of Bi-functional Degraders Targeting the CNS By dev@sirosolutions.com / December 11, 2024
